Tirzepatide: Incretin-Based Metabolic Control
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents the most advanced incretin-based therapy available for metabolic research:
Appetite Regulation: GLP-1 receptor activation in the brain's hypothalamus suppresses appetite and reduces food intake. This is the primary driver of weight reduction in clinical trials.
Insulin Sensitivity: GIP receptor activation enhances pancreatic beta-cell function and improves insulin secretion kinetics. Combined with GLP-1's effects, this produces significant glycaemic improvements.
Fat Metabolism: GIP receptors on adipose tissue improve lipid handling and fat storage efficiency. This dual mechanism explains tirzepatide's superior efficacy over GLP-1-only compounds.
Clinical Evidence: SURPASS and SURMOUNT trials demonstrated 15-21% body weight reduction and HbA1c improvements of 1.9-2.6% -- the strongest data of any metabolic peptide.
ORYN Tirzepatide Pen: 10 mg multi-dose pen, 30-day supply, EUR 169. >99% purity, GMP manufactured.
NAD+: Mitochondrial Energy Restoration
NAD+ approaches metabolism from the cellular energy level -- the most fundamental layer of metabolic function:
ATP Production: NAD+ is an essential electron carrier in the mitochondrial electron transport chain. Without adequate NAD+, cells cannot efficiently produce ATP -- the energy currency that powers every metabolic process.
Sirtuin Activation: NAD+ is the obligate substrate for sirtuins, which regulate metabolic efficiency, fat oxidation, glucose homeostasis, and mitochondrial biogenesis. Age-related NAD+ decline directly impairs sirtuin function.
Metabolic Flexibility: Adequate NAD+ levels support the ability to switch between fat and glucose oxidation -- a key marker of metabolic health that declines with age.
Systemic Benefits: Beyond metabolism, NAD+ supports DNA repair, immune function, and cognitive performance -- making it a broader intervention than metabolic-specific compounds.
ORYN NAD+ Pen: 250 mg pre-mixed pen, 30-day supply, EUR 189. Pen delivery ensures bioavailability.
Choosing Between or Combining Both
The choice between tirzepatide and NAD+ depends entirely on the primary research endpoint:
Choose Tirzepatide if: - Weight management is the primary research focus - Glycaemic control and insulin sensitivity are key endpoints - Body composition changes (fat loss) are being measured - Clinical-grade efficacy data is important for the protocol
Choose NAD+ if: - Cellular energy and mitochondrial function are the primary focus - Longevity pathways (sirtuins) are being studied - DNA repair and genomic stability are endpoints - A broader, systemic approach to metabolic health is needed - Cognitive function is a secondary endpoint
Combination Rationale: Some researchers study both together -- tirzepatide optimising macroscopic metabolic parameters (weight, insulin, appetite) while NAD+ supports the underlying cellular energy infrastructure. At EUR 169 + EUR 189 = EUR 358, this provides coverage of both incretin and mitochondrial metabolic pathways.
